RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …

Summary KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …

Despite significant advancements in the treatment of other cancers, pancreatic ductal
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …

Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low
response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors …

Lung cancer remains the leading cause of cancer death globally. More than 50% of new
cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor …

Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the
changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a …

Simple Summary Pancreatic cancer is predicted to be the second-highest cause of cancer
mortality in the US by 2040. It is driven by various mutations including KRAS, TP53, SMAD4 …

Present in all eukaryotic cells, the integrated stress response (ISR) is a highly coordinated
signaling network that controls cellular behavior, metabolism and survival in response to …

Simple Summary KRAS mutations have critical roles in the etiology of cancers such as
NSCLC, CRC, and PDAC. However, therapeutic targeting of KRAS has proven difficult due …

Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic
Melanoma Page 1 Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer …